U.S. Patent Awarded to Novogen; Enables Company to Offer Licensing Rights On Menopause Health Claims Related to Isoflavones

STAMFORD, Conn., May 20 /PRNewswire-FirstCall/ -- Pharmaceutical company Novogen Limited (Nasdaq: NVGN) has been granted a patent in the U.S. over the use of its isoflavone technology in the treatment of the symptoms of menopause and pre-menstrual syndrome (PMS).

The patent applies to the isoflavones genistein, daidzein, formononetin and biochanin, all of which are used commonly in pharmaceutical preparations and health supplements such as tablets, capsules, drinks and foodstuffs for the alleviation of the adverse symptoms of menopause and PMS.

Novogen pioneered the research, development, manufacture and marketing of isoflavone technology through three of its own proprietary dietary supplements, Promensil(TM) for the treatment of the symptoms of menopause, Rimostil(TM), for the maintenance of bone and heart health in women and Trinovin(TM) for the maintenance of prostate and urinary health for men.

Novogen also has licensed part of its technology to the DuPont controlled company Solae for which it is receiving royalty payments.

Novogen's managing director, Mr. Christopher Naughton, said isoflavone supplements are widely used by women worldwide seeking a safe alternative to hormone replacement therapy for the maintenance of health and well being during and after menopause.

"The granting of the patent adds value to product marketing and also strengthens potential for possible further licensing transactions," Mr. Naughton said.

"While Novogen's principal corporate focus is on clinical trialling of various components of its phenolic hormone technology, it is a major competitive advantage to have a suite of patents around the isoflavone platform," Mr. Naughton added.

Novogen's isoflavone products are marketed globally and the company coordinates and manages its research and development programs using the expertise and clinical research capabilities of universities and hospitals in Australia and key international locations.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings under "Risk Factors", including risks relating to the early stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.